Sofwave In The First Quarter: Profit Came Back, Cash Still Has To Follow

Sofwave opened 2026 with a quarter that strengthens its commercial story, but does not close the discussion about earnings quality. Revenue rose to $24.4 million, usage fees reached $11 million, and net income moved to $1.3 million after a loss in the comparable quarter. That is a useful proof point that the fourth quarter of 2025 was not only a year-end sales event, but part of a maturing platform that sells both systems and actual utilization. Cash did not yet join that picture: operating cash flow was negative by $0.7 million, mainly because of working capital and payment of bonuses accrued in 2025. The quarter therefore does not change the central read from the previous annual analysis: the company has moved into profitability, but 2026 is still a proof year. The near-term test is continued growth alongside usage fees above 40% of revenue, clearer adoption signs for Pure Impact, and conversion of reported profit into positive cash flow without temporary help from suppliers, option exercises, or timing.

The Model Is Less Dependent On System Sales

The company sells non-invasive ultrasound systems for aesthetic skin tightening and rejuvenation, and also charges usage fees on pulses and treatments consumed after the system is purchased. That is the main economic difference between a regular medical-device sale and a utilization platform: the system sale opens the door, but the higher-quality value comes when the clinic continues treating patients, ordering pulses, and returning to the platform after the initial transaction.

That line strengthened in the first quarter. Usage fees were $11 million, about 45% of revenue, and grew 56% year over year. System sales were about $13.4 million and grew 39%. Both layers are growing, but the utilization layer is growing faster. This was the key question after 2025: whether the installed base continues to mature, or whether growth remains mostly a matter of selling more devices.

The broader utilization metrics provided by the company point in the same direction: about 2,900 Sofwave systems sold since commercialization and about 865,000 cumulative treatments. These are not audited revenue metrics, but they help frame the economics. An expanding installed base and rising treatment volume allow the company to grow revenue without relying every quarter only on new system placements.

The geographic mix adds an important layer. U.S. revenue was $10.8 million, about 44% of the quarter. East Asia contributed $9.1 million, Europe and the Middle East contributed $3.2 million, and other markets contributed $1.2 million. The U.S. market is still very important, but the quarter is not only a U.S. story. That reduces reliance on one territory, while still leaving U.S. tariffs or local market conditions capable of moving margins quickly.

Profit Returned, But Cash Has Not Yet Followed

The strong part of the quarter is operating leverage. Revenue grew 46%, while research and development expenses rose 22%, sales and marketing rose 25%, and general and administrative expenses rose 7%. Operating expenses fell from about 82% of revenue in the comparable quarter to about 68% this quarter. This is no longer a company where every additional dollar of growth is immediately absorbed by expenses, and operating income moved to $1.6 million after an operating loss of $1.0 million a year earlier.

The cash proof is weaker than the profit proof. Net income was $1.3 million, but operating cash flow was negative by $0.7 million. The quarter’s all-in cash picture includes operating cash flow, $0.2 million of property and equipment purchases, $0.2 million of lease repayments, interest received, option-exercise proceeds, and currency effects. After all of that, cash decreased by only $0.1 million, so there is no liquidity pressure. Still, this was not yet a quarter in which the business proved it can fund growth from its own operating cash generation.

Working capital explains most of the gap. Inventory and other receivables consumed cash, and accrued liabilities fell mainly because bonuses accrued in 2025 were paid. Supplier balances partially supported cash flow. This is not a simple negative conclusion. Part of the pressure comes from timing and a payment tied to the prior year, and part reflects the need to fund growth through inventory, receivables, and service infrastructure. For the new profitability to earn a cleaner market premium, it needs to start appearing in operating cash flow too.

The balance sheet gives the company time to prove that. At the end of March, it had $34.6 million of cash and cash equivalents, plus a $0.5 million restricted short-term deposit. The main financial liabilities are leases, not bank debt. The near-term risk is therefore not survival financing. The practical bottleneck is conversion quality: whether growth that is now reaching operating profit can continue without drawing more and more working capital.

Tariffs And Pure Impact Test Growth Quality

Gross profitability remains high, but there is already some modest erosion. Gross margin was 75.0%, compared with 76.3% in the comparable quarter. That is still a strong margin for an aesthetic medical-device company that sells physical systems, provides service, and expands geographically. The next checkpoint is stability around 75% after another quarter of tariffs, service, and logistics.

The reason is U.S. tariffs. The company is currently subject to a 10% tariff on certain goods imported into the United States, and it does not have an estimate for possible changes in tariff policy or their effect. Because the U.S. is a material revenue geography, this is not a generic macro note. Holding around 75% despite tariffs, service, and logistics would strengthen the model’s resilience. Sharper erosion would suggest that part of the growth is more expensive than the revenue line implies.

Pure Impact is the second trigger. In the quarter, the company recorded an $80,000 royalty liability to a related company for sales of Pure Impact products. The line is small, but it matters because it proves that the product is already generating sales rather than remaining only a marketing story. On the other hand, it does not yet prove a second engine. The company does not disclose how many units were sold, how many treatment hours were purchased, the product’s revenue contribution, or its contribution to usage among existing customers.

That is where the numbers should not be front-run. Management describes Pure Impact VIP as a standalone system for treating several body areas, and frames the body category around demand linked to weight-loss trends and combined skin-and-muscle treatments. That could open a wider market for the company, but as of the first quarter the economic proof is still limited. The positive signal is that the product is already selling. The blocker is the absence of adoption metrics that separate a meaningful growth layer from an early add-on beside the core engine.

There is also a capital-markets trigger: the board authorized management to examine the preparation and confidential submission of a draft F-1 in the United States, and the shareholder meeting approved a reporting-framework transition that would become effective subject to completion of a U.S. public offering and listing. This is not a completed capital raise and not an actual listing, so it should not become the thesis. But the review itself raises the proof bar: a company seeking broader U.S. market access will need to show not only growth and profit, but cleaner cash conversion and better disclosure around new growth engines.

Conclusion

The first quarter strengthens the positive direction, but leaves the central test open. The company is proving that usage fees are not a small add-on to system sales, but nearly half of revenue and growing faster than the initial sale. It is also proving that operating expenses are starting to shrink relative to revenue, so growth is reaching operating profit. Together, these support the read of a maturing platform.

The other side is that earnings quality is still not clean enough. Operating cash flow is negative, working capital is consuming cash, U.S. tariffs may test gross margin, and Pure Impact still lacks clear commercial adoption metrics. That is why 2026 looks less like a harvest year and more like a proof year: another quarter or two with usage fees above 40%, gross margin around 75%, and operating cash flow turning positive would materially improve the quality of the story. A decline in usage-fee mix, sharper gross-margin erosion, or a continued gap between profit and cash flow would weaken the claim that the company has already moved into a more mature phase.